Claims
- 1. A method of treating acute, chronic and/or neuropathic pain in a mammal experiencing chronic, acute and/or neuropathic pain comprising administering to said mammal an effective amount of an NR2B selective N-methyl-D-aspartate (NMDA) receptor antagonist having a ratio of NR2B receptor activity to α1-adrenergic receptor activity of at least about 3:1.
- 2. The method of claim 1, wherein said NR2B subtype selective NMDA receptor antagonist is a compound of the formula
18
- 3. The method of claim 2, wherein said compound is (+)-(1S, 2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol or a pharmaceutically acceptable acid addition salt thereof.
- 4. The method of claim 2, wherein said compound is (1S, 2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol or a pharmaceutically acceptable acid addition salt thereof.
- 5. The method of claim 2, wherein said compound is (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chroman-4,7-diol or a pharmaceutically acceptable acid addition salt thereof.
- 6. The method of claim 2, wherein said compound is (1R*,2R*)-1-(4-hydroxy-3-methylphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-propan-1-ol-mesylate
- 7. The method of claim 1, wherein said ratio of NR2B receptor activity to α1-adrenergic receptor activity is at least about 5:1.
Parent Case Info
[0001] This application is based on U.S. Provisional Patent Application Ser. No. 60/102,630, filed Oct. 1, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60102630 |
Oct 1998 |
US |